Extended Data Fig. 4: Cooperative IL-15 signaling is needed to confer the therapeutic benefit of a TREM2-deficient setting.
From: TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer
(a) Relative expression of Il15 by mature mregDCs, as determined by scRNA-seq profiling of MNPs in the tumor-bearing lungs of WT and KO mice (Fig. 3C). (b) Representative H&E images of tumor-bearing lungs of WT, isotype antibody (n = 4), WT mice that received the IL-15 neutralizing antibody (n = 4), KO, isotype antibody (n = 4), KO mice that received the IL-15 neutralizing antibody (n = 5) (left). Quantification of the tumor area as a percent of the total area of the lung cross-section (right) is shown. (mean ± standard error of mean (S.E.M.); unpaired two-tailed t-test at a 95% confidence interval). (c) Flow cytometric quantification of NK cells, as a relative frequency of CD45+ immune cells, in the KP-GFP tumor-bearing lungs of isotype control WT and KO mice and WT and KO mice treated with the αIL-15 antibody. (n = 4-5 mice per group, mean ± standard error of mean (S.E.M.); unpaired two-tailed t-test at a 95% confidence interval. Data shown is representative of two independent experiments).
